Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet
Ji Hye Han, Tae Jung Oh, Ghayoung Lee, et al.
Diabetologia (2016) Vol. 60, Iss. 2, pp. 364-376
Open Access | Times Cited: 241

Showing 1-25 of 241 citing articles:

COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Soo Lim, Jae Hyun Bae, Hyuk‐Sang Kwon, et al.
Nature Reviews Endocrinology (2020) Vol. 17, Iss. 1, pp. 11-30
Open Access | Times Cited: 929
Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies
Suowen Xu, Iqra Ilyas, Peter J. Little, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 3, pp. 924-967
Open Access | Times Cited: 667
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Martín Cowie, Miles Fisher
Nature Reviews Cardiology (2020) Vol. 17, Iss. 12, pp. 761-772
Closed Access | Times Cited: 574
Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease
Sebastian Steven, Katie Frenis, Matthias Oelze, et al.
Oxidative Medicine and Cellular Longevity (2019) Vol. 2019, pp. 1-26
Open Access | Times Cited: 546
The Role of Oxidative Stress and Antioxidants in Diabetic Wound Healing
Liling Deng, Chenzhen Du, Peiyang Song, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 419
Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction
Salva R. Yurista, Herman H.W. Silljé, Silke U. Oberdorf‐Maass, et al.
European Journal of Heart Failure (2019) Vol. 21, Iss. 7, pp. 862-873
Open Access | Times Cited: 276
SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition
Issei Tomita, Shinji Kume, Sho Sugahara, et al.
Cell Metabolism (2020) Vol. 32, Iss. 3, pp. 404-419.e6
Open Access | Times Cited: 268
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
Fabrice Bonnet, André Scheen
Diabetes & Metabolism (2018) Vol. 44, Iss. 6, pp. 457-464
Closed Access | Times Cited: 259
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
Sebastian Steven, Matthias Oelze, Alina Hanf, et al.
Redox Biology (2017) Vol. 13, pp. 370-385
Open Access | Times Cited: 246
Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
Sandra Rayego‐Mateos, José Luis Morgado‐Pascual, Lucas Opazo-Ríos, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 11, pp. 3798-3798
Open Access | Times Cited: 223
Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
Narjes Nasiri‐Ansari, Chrysa Nikolopoulou, Katerina Papoutsi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 818-818
Open Access | Times Cited: 223
Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
Sarah J. Mancini, D. H. A. Boyd, Omar J. Katwan, et al.
Scientific Reports (2018) Vol. 8, Iss. 1
Open Access | Times Cited: 204
Inflammatory Targets in Diabetic Nephropathy
Javier Donate‐Correa, Desirée Luis-Rodríguez, Ernesto Martín‐Núñez, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 2, pp. 458-458
Open Access | Times Cited: 180
Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells
Laween Uthman, Anna Homayr, Rio P. Juni, et al.
Cellular Physiology and Biochemistry (2019) Vol. 53, Iss. 5, pp. 865-886
Open Access | Times Cited: 158
Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages
Elaheh Abdollahi, Fariborz Keyhanfar, Ali‐Akbar Delbandi, et al.
European Journal of Pharmacology (2022) Vol. 918, pp. 174715-174715
Closed Access | Times Cited: 90
Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization
Ameya Kulkarni, Sandra Aleksić, David M. Berger, et al.
Aging Cell (2022) Vol. 21, Iss. 4
Open Access | Times Cited: 71
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Alberto Preda, Fabrizio Montecucco, Federico Carbone, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 5, pp. 443-460
Open Access | Times Cited: 34
Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?
Paschalis Karakasis, Nikolaos Fragakis, Κωνσταντίνος Κούσκουρας, et al.
Clinical Therapeutics (2024) Vol. 46, Iss. 11, pp. 841-850
Closed Access | Times Cited: 16
Adiponectin, lipids and atherosclerosis
Niki Katsiki, Christos S. Mantzoros, Dimitri P. Mikhailidis
Current Opinion in Lipidology (2017) Vol. 28, Iss. 4, pp. 347-354
Closed Access | Times Cited: 154
Targeting inflammation in diabetic nephropathy: a tale of hope
Juan Antonio Moreno, Carmen Gómez‐Guerrero, Sebastián Mas, et al.
Expert Opinion on Investigational Drugs (2018) Vol. 27, Iss. 11, pp. 917-930
Closed Access | Times Cited: 146
SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob−/− mice
Damilola D. Adingupu, Sven Göpel, Julia Grönros, et al.
Cardiovascular Diabetology (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 142
Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats
Alana Aragón‐Herrera, Sandra Feijóo‐Bandín, Manuel Otero Santiago, et al.
Biochemical Pharmacology (2019) Vol. 170, pp. 113677-113677
Closed Access | Times Cited: 140
Revisiting pharmacology of oxidative stress and endothelial dysfunction in cardiovascular disease: Evidence for redox-based therapies
Andreas Daiber, Stefan Chłopicki
Free Radical Biology and Medicine (2020) Vol. 157, pp. 15-37
Open Access | Times Cited: 135
Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice
Narjes Nasiri‐Ansari, Georgios K. Dimitriadis, Georgios Agrogiannis, et al.
Cardiovascular Diabetology (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 129
Sodium–glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways
Habib Yaribeygi, Alexandra E. Butler, Stephen L. Atkin, et al.
Journal of Cellular Physiology (2018) Vol. 234, Iss. 1, pp. 223-230
Open Access | Times Cited: 129
Page 1 - Next Page

Scroll to top